Kronos Bio Ebit Over Time
| KRON Stock | USD 1.05 0.02 1.87% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kronos Bio Performance and Kronos Bio Correlation. Kronos |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebit Analysis
Compare Kronos Bio and related stocks such as Cyclerion Therapeutics, Larimar Therapeutics, and Addex Therapeutics Ebit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYCN | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (63.6 M) | (93.9 M) | (115.3 M) | (125 M) | (83.6 M) | (55.7 M) | (18.2 M) | (9.6 M) | (10.1 M) |
| LRMR | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (35.5 M) | (73.8 M) | (57.1 M) | (53.9 M) | (62.7 M) | (23.2 M) | (42.8 M) | (50.5 M) | (36.5 M) | (41.8 M) | (43.8 M) |
| ADXN | (20.6 M) | (30.9 M) | (27 M) | (14.5 M) | (1.8 M) | (2.6 M) | (3.1 M) | (3.2 M) | (1.4 M) | (14.8 M) | (12.8 M) | (15.3 M) | (20.6 M) | (10.5 M) | (11.1 M) |
| ACHL | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (13.8 M) | (33.7 M) | (61.1 M) | (82.1 M) | (75.2 M) | (71.4 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (23.2 M) | (37.5 M) | (41.2 M) | (69.3 M) | (75.9 M) | (62.7 M) | (65.9 M) |
| CTMX | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (29.8 M) | (33.6 M) | (57.2 M) | (46.3 M) | (77.9 M) | (110.9 M) | (83.4 M) | (83.8 M) | (101.3 M) | (6.5 M) | (6.8 M) |
| SPRO | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (33.8 M) | (41.7 M) | (42.8 M) | (63.2 M) | (79.1 M) | (88.3 M) | (43.8 M) | 25.4 M | 26.7 M |
| ASMB | (7.2 M) | (33.7 M) | (24.8 M) | (19.4 M) | (24 M) | (29.6 M) | (44.1 M) | (51.6 M) | (92.7 M) | (102.7 M) | (65.5 M) | (92.4 M) | (94.1 M) | (64.6 M) | (67.9 M) |
| REPL | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (19 M) | (28 M) | (53.1 M) | (80.6 M) | (119 M) | (172.8 M) | (232.9 M) | (221.2 M) |
| NVCT | (34 K) | (34 K) | (34 K) | (34 K) | (34 K) | (34 K) | (34 K) | (34 K) | (34 K) | (34 K) | (34 K) | (12.9 M) | (19.2 M) | (21.9 M) | (20.8 M) |
| LYRA | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (16.5 M) | (22.2 M) | (43.6 M) | (55 M) | (65.5 M) | (62.3 M) |
| GOSS | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (83 K) | (6.7 M) | (97.3 M) | (186.1 M) | (238.2 M) | (214.5 M) | (215.5 M) | (173.8 M) | (182.4 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.1 M) | (28.7 M) | (53.8 M) | (75 M) | (107.7 M) | (167.9 M) | (222.6 M) | (211.5 M) |
| INBX | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (19.7 M) | (29.4 M) | (43.7 M) | (67.4 M) | (76.6 M) | (129.1 M) | (207.9 M) | (197.5 M) |
| MRUS | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (21.1 M) | (25.1 M) | (29.3 M) | (51 M) | (28.1 M) | (58.7 M) | (62.4 M) | (79.2 M) | (149.5 M) | (151.7 M) | (144.2 M) |
| LYEL | (105.2 M) | (105.2 M) | (105.2 M) | (105.2 M) | (105.2 M) | (105.2 M) | (105.2 M) | (105.2 M) | (105.2 M) | (105.2 M) | (215.1 M) | (214.5 M) | (183.1 M) | (247 M) | (259.4 M) |
| GBIO | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (37.3 M) | (62.3 M) | (81.1 M) | (119.1 M) | (141.2 M) | (138.6 M) | (145.5 M) |
| ERAS | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (13.3 M) | (101.7 M) | (122.8 M) | (242.8 M) | (125 M) | (131.3 M) |
| CCCC | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (35.5 M) | (65.7 M) | (81.7 M) | (131.9 M) | (129.8 M) | (123.3 M) |
| EWTX | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (17.2 M) | (43.2 M) | (22.1 M) | (114.5 M) | (108.8 M) |
Kronos Bio and related stocks such as Cyclerion Therapeutics, Larimar Therapeutics, and Addex Therapeutics Ebit description
My Equities
My Current Equities and Potential Positions
| Kronos Bio | KRON |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.05
Check out Kronos Bio Performance and Kronos Bio Correlation. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Kronos Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.